191 related articles for article (PubMed ID: 25418598)
41. Plasma cell leukemia: update on biology and therapy.
Mina R; D'Agostino M; Cerrato C; Gay F; Palumbo A
Leuk Lymphoma; 2017 Jul; 58(7):1538-1547. PubMed ID: 27819179
[TBL] [Abstract][Full Text] [Related]
42. Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant.
Mehta B; Mahadeo K; Zaw R; Tang S; Kapoor N; Abdel-Azim H
Pediatr Blood Cancer; 2014 Dec; 61(12):2324-5. PubMed ID: 25131654
[No Abstract] [Full Text] [Related]
43. Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Kettle JK; Finkbiner KL; Klenke SE; Baker RD; Henry DW; Williams CB
J Oncol Pharm Pract; 2009 Sep; 15(3):131-41. PubMed ID: 19276138
[TBL] [Abstract][Full Text] [Related]
44. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic strategies for the treatment of multiple myeloma.
Saini N; Mahindra A
Discov Med; 2013 Apr; 15(83):251-8. PubMed ID: 23636142
[TBL] [Abstract][Full Text] [Related]
46. Emerging drugs in multiple myeloma.
Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
[TBL] [Abstract][Full Text] [Related]
47. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang L; Ran X; Wang B; Sheng Z; Liu L
Hematol Oncol; 2012 Jun; 30(2):57-61. PubMed ID: 21809367
[TBL] [Abstract][Full Text] [Related]
48. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
[TBL] [Abstract][Full Text] [Related]
49. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
50. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
51. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
[TBL] [Abstract][Full Text] [Related]
52. [Successful treatment with bortezomib for a patient with plasma cell leukemia accompanied by severe hyperbilirubinemia].
Mino T; Sakai A; Kinoshita M; Yoshida T; Mihara K; Imagawa J; Kimura A
Rinsho Ketsueki; 2012 Jan; 53(1):92-6. PubMed ID: 22374531
[TBL] [Abstract][Full Text] [Related]
53. Primary plasma cell leukemia in the era of new drugs: has something changed?
Musto P; Pagano L; Petrucci MT; Morabito F; Caravita T; Di Raimondo F; Baldini L; Tosi P; Bringhen S; Offidani M; Omede' P; Neri A; D'Auria F; Bochicchio GB; Cavo M; Boccadoro M; Palumbo A
Crit Rev Oncol Hematol; 2012 May; 82(2):141-9. PubMed ID: 21719304
[TBL] [Abstract][Full Text] [Related]
54. Plasma cell leukemia: Clinicopathologic, immunophenotypic and cytogenetic characteristics of 4 cases.
Alghasham N; Alnounou R; Alzahrani H; Alsharif F
Hematol Oncol Stem Cell Ther; 2015 Jun; 8(2):71-7. PubMed ID: 25929729
[TBL] [Abstract][Full Text] [Related]
55. Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy.
Ueno T; Sugio Y; Ohta T; Uehara Y; Ohno Y
Int J Hematol; 2021 Jun; 113(6):941-944. PubMed ID: 33483877
[TBL] [Abstract][Full Text] [Related]
56. Primary plasma cell leukemia 2.0: advances in biology and clinical management.
Neri A; Todoerti K; Lionetti M; Simeon V; Barbieri M; Nozza F; Vona G; Pompa A; Baldini L; Musto P
Expert Rev Hematol; 2016 Nov; 9(11):1063-1073. PubMed ID: 27759436
[TBL] [Abstract][Full Text] [Related]
57. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Fernández de Larrea C; Kyle RA; Durie BG; Ludwig H; Usmani S; Vesole DH; Hajek R; San Miguel JF; Sezer O; Sonneveld P; Kumar SK; Mahindra A; Comenzo R; Palumbo A; Mazumber A; Anderson KC; Richardson PG; Badros AZ; Caers J; Cavo M; LeLeu X; Dimopoulos MA; Chim CS; Schots R; Noeul A; Fantl D; Mellqvist UH; Landgren O; Chanan-Khan A; Moreau P; Fonseca R; Merlini G; Lahuerta JJ; Bladé J; Orlowski RZ; Shah JJ;
Leukemia; 2013 Apr; 27(4):780-91. PubMed ID: 23288300
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib is effective in primary plasma cell leukemia.
Finnegan DP; Kettle P; Drake M; Matthews C; Alexander HD; Popat R; Cavanagh JD; Wachsman W; Morris TC
Leuk Lymphoma; 2006 Aug; 47(8):1670-3. PubMed ID: 16966282
[No Abstract] [Full Text] [Related]
59. Primary plasma cell leukaemia in a 39-year-old man.
Kasinathan G
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32709663
[TBL] [Abstract][Full Text] [Related]
60. Plasma cell leukemia mimicking hairy cell leukemia.
Hanbali A; Alrajeh A; Rasheed W
Hematol Oncol Stem Cell Ther; 2015 Jun; 8(2):91-2. PubMed ID: 26013472
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
